All In Biotech

Drug Trial Radar · NCT00028743

Combination Chemotherapy Regimens in Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

A Phase III Study of Cisplatin Plus Topotecan Followed by Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Carboplatin as First Line Chemotherapy in Women With Newly Diagnosed Advanced Epithelial Ovarian Cancer

Last checked: Nov 19, 2026Latest source record: Apr 2, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 819 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

819

Actual

Start

Aug 31, 2001

Primary completion

Mar 5, 2008

Study completion Jan 10, 2013

Sponsor

Lead sponsor
NCIC Clinical Trials GroupResearch network
Sponsor type
Research network
Collaborators
European Organisation for Research and Treatment of Cancer - EORTC; Grupo Español de Investigación en Cáncer de Ovario
First posted
Jan 27, 2003

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving the drugs in different combinations may kill more tumor cells. It is not yet known which combination chemotherapy regimen is more effective in treating ovarian epithelial, primary peritoneal, or fallopian tube cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of different combination chemotherapy regimens in treating patients who have stage IIB, stage III, or stage IV ovarian epithelial cancer , primary peritoneal cancer, or fallopian tube cancer.

Conditions

  • Fallopian Tube Cancer
  • Ovarian Cancer
  • Peritoneal Cavity Cancer

Interventions

  • carboplatinDrug

    Arm 1 = 4 cycles vs Arm 2 = 8 cycles AUC5 (30 mins) day 1 of 21 day cycle

  • cisplatinDrug

    4 cycles 50mg/m2 (60 mins) day 1 of 21 day cycle

  • paclitaxelDrug

    Arm 1 = 4 cycles vs Arm 2 = 8 cycles 175mg/m2 (3 hours) day 1 of 21 day cycle

  • topotecan hydrochlorideDrug

    4 cycles .75mg/m2 (30 mins) days 1-5 of 21 day cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression free survivalTime frame: Mar 2008

Locations

28 sites in 1 country. Site status is shown where the registry gives one.

  • Tom Baker Cancer Centre

    Calgary, Alberta, Canada

  • Cross Cancer Institute

    Edmonton, Alberta, Canada

  • BCCA - Cancer Centre for the Southern Interior

    Kelowna, British Columbia, Canada

  • Lions Gate Hospital

    North Vancouver, British Columbia, Canada

  • BCCA - Fraser Valley Cancer Centre

    Surrey, British Columbia, Canada

  • BCCA - Vancouver Cancer Centre

    Vancouver, British Columbia, Canada

  • CancerCare Manitoba

    Winnipeg, Manitoba, Canada

  • The Moncton Hospital

    Moncton, New Brunswick, Canada

  • Atlantic Health Sciences Corporation

    Saint John, New Brunswick, Canada

  • Dr. H. Bliss Murphy Cancer Centre

    St. John's, Newfoundland and Labrador, Canada

  • QEII Health Sciences Center

    Halifax, Nova Scotia, Canada

  • Northeast Cancer Center Health Sciences

    Greater Sudbury, Ontario, Canada

  • Juravinski Cancer Centre at Hamilton Health Sciences

    Hamilton, Ontario, Canada

  • Cancer Centre of Southeastern Ontario at Kingston

    Kingston, Ontario, Canada

  • Grand River Regional Cancer Centre

    Kitchener, Ontario, Canada

  • London Regional Cancer Program

    London, Ontario, Canada

  • Ottawa Health Research Institute - General Division

    Ottawa, Ontario, Canada

  • Niagara Health System

    St. Catharines, Ontario, Canada

  • Thunder Bay Regional Health Science Centre

    Thunder Bay, Ontario, Canada

  • Univ. Health Network-Princess Margaret Hospital

    Toronto, Ontario, Canada

  • Windsor Regional Cancer Centre

    Windsor, Ontario, Canada

  • PEI Cancer Treatment Centre,Queen Elizabeth Hospital

    Charlottetown, Prince Edward Island, Canada

  • CHUM - Hopital Notre-Dame

    Montreal, Quebec, Canada

  • Hopital du Sacre-Coeur de Montreal

    Montreal, Quebec, Canada

  • CHUQ-Pavillon Hotel-Dieu de Quebec

    Québec, Quebec, Canada

  • Centre hospitalier universitaire de Sherbrooke

    Sherbrooke, Quebec, Canada

  • Allan Blair Cancer Centre

    Regina, Saskatchewan, Canada

  • Saskatoon Cancer Centre

    Saskatoon, Saskatchewan, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.